LAB STANDARD BIOTOOLS INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1162194 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.2%
TTM net income YoY203.8%
TTM EPS YoY203.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin52.2%
Operating margin-97.5%
Net margin157.6%
FCF margin-77.8%
EBITDA margin-91.3%
Returns
ROE27.9%
ROA22.7%
ROIC (approx.)-23.4%
Asset turnover0.14x
Leverage & solvency
Liabilities / assets12.5%
Debt / equity0.00x
Current ratio9.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.48x
Accruals ratio33.6%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $19.39M | $20.10M | $21.15M | $23.80M | $19.55M | $21.76M | $20.22M | $24.78M |
| Cost of revenue | $8.56M | $9.57M | $9.84M | $12.41M | $10.07M | $11.13M | $9.17M | $13.42M |
| Gross profit | $10.83M | $10.54M | $11.31M | $11.38M | $9.48M | $10.63M | $11.05M | $11.36M |
| R&D expense | $2.08M | $1.98M | $2.12M | $7.97M | $6.36M | $6.22M | $5.44M | $7.04M |
| SG&A expense | $16.84M | $16.39M | $18.61M | $25.34M | $26.59M | $28.11M | $29.82M | $27.32M |
| Operating income | -$19.77M | -$25.39M | -$12.50M | -$24.64M | -$32.94M | -$25.70M | -$26.97M | -$26.08M |
| Pretax income | -$14.95M | -$21.43M | -$14.62M | -$22.03M | -$32.90M | -$18.28M | -$23.49M | -$26.90M |
| Income tax | $27,000 | $90,000 | $11,000 | -$35.93M | -$1.22M | -$609,000 | -$119,000 | $272,000 |
| Net income | $13.48M | -$26.76M | $127.07M | $19.28M | -$34.69M | -$33.46M | -$26.03M | -$34.07M |
| EBITDA | -$18.57M | -$24.11M | -$11.09M | -$23.35M | -$31.44M | -$23.70M | -$23.70M | -$22.94M |
| EPS (basic) | 0.03 | -0.07 | 0.33 | — | -0.09 | -0.09 | -0.07 | — |
| EPS (diluted) | 0.03 | -0.07 | 0.33 | — | -0.09 | -0.09 | -0.07 | — |
| Weighted avg. shares (diluted) | 393.56M | 390.88M | 388.20M | — | 382.63M | 380.50M | 378.23M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $267.49M | $270.03M | $265.77M | $120.86M | $132.01M | $161.20M | $153.47M | $168.82M |
| Short-term investments | $193.62M | $206.69M | $189.40M | $66.71M | $65.48M | $78.47M | $107.18M | $126.15M |
| Receivables | $12.98M | $15.75M | $16.64M | $13.43M | $13.54M | $14.61M | $35.48M | $14.74M |
| Inventory | $17.62M | $17.10M | $18.59M | $19.98M | $25.42M | $24.17M | $42.12M | $20.74M |
| Current assets | $497.30M | $516.87M | $521.45M | $454.26M | $472.44M | $506.04M | $344.02M | $375.88M |
| PP&E, net | $13.24M | $15.30M | $17.10M | $19.27M | $20.74M | $22.68M | $43.59M | $22.77M |
| Goodwill | — | — | — | — | — | — | $111.72M | $111.30M |
| Intangibles | — | — | — | — | — | — | $28.06M | $28.95M |
| Total assets | $635.33M | $627.22M | $639.11M | $567.75M | $539.64M | $556.97M | $579.60M | $612.35M |
| Current liabilities | $51.02M | $56.80M | $42.20M | $108.31M | $107.97M | $98.02M | $56.24M | $65.89M |
| Long-term debt | — | — | — | — | — | — | — | $299,000 |
| Total debt | — | — | — | — | — | — | — | $299,000 |
| Total liabilities | $79.58M | $87.25M | $77.99M | $143.46M | $139.98M | $132.43M | $125.00M | $140.62M |
| Shareholders' equity | $555.75M | $539.97M | $561.12M | $424.29M | $399.66M | $424.54M | $454.60M | $471.72M |
| Net debt | — | — | — | — | — | — | — | -$168.52M |
| Shares outstanding | 394.67M | 392.12M | 390.14M | 386.38M | 383.61M | 381.69M | 379.09M | 377.53M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.16M | -$10.31M | -$46.60M | -$1.19M | -$22.20M | -$20.67M | -$30.28M | -$14.06M |
| Capital expenditure | $0 | $344,000 | $570,000 | $476,000 | $886,000 | $1.89M | $5.05M | $3.38M |
| Free cash flow | -$6.16M | -$10.65M | -$47.17M | -$1.67M | -$23.09M | -$22.55M | -$35.34M | -$17.44M |
| Investing cash flow | $4.83M | $14.41M | $191.09M | -$8.04M | -$6.68M | $27.50M | $14.62M | $25.73M |
| Financing cash flow | -$598,000 | -$138,000 | -$40,000 | $620,000 | -$112,000 | $108,000 | -$46,000 | -$54.52M |
| Depreciation & amortization | $1.20M | $1.27M | $1.41M | $1.29M | $1.50M | $2.00M | $3.27M | $3.14M |
| Stock-based compensation | $3.72M | $4.05M | $8.82M | $5.74M | $7.54M | $5.37M | $9.01M | $7.47M |
| Share buybacks | — | — | — | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.